Lorenzo Galluzzi from the Weill Cornell Medical College in New York, USA, harnesses an innovative mouse model of hormone receptor (HR)-positive breast cancer with unique translational potential and determine immunological mechanisms of resistances to CDK4/6 inhibitors, a novel class of targeted anti-cancer agents that have been shown to extend the OS of patients with HR+ breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.